Up today 98 cents or 25%. Investors are cashing in on upcoming data to be presented over the next couple of months. ANDS volume nearly tripled from the 3 month average.
Anadys, a biopharmaceutical company, engages in discovering, developing, and commercializing small molecule medicines for the treatment of viral diseases and cancer. The company has core expertise in structure-based drug design coupled with medicinal chemistry and Toll-Like Receptor-based small molecule therapeutics. Its clinical development program includes ANA380 for the treatment of HBV, currently in mid-stage clinical development. Anadys Pharmaceuticals also focuses on the development of the ANA975 program for the treatment of HCV and HBV. In addition, it has an oncology program with the oral TLR-7 agonist, ANA773; a direct antiviral HCV program around a series of non-nucleoside NS5B inhibitors; a program with the oral TLR-7 agonist with potential utility in viral and non-viral applications; and a HIV program focused on viral entry in pre-clinical development.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment